Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $64,621 | 15 | 82.0% |
| Travel and Lodging | $5,728 | 13 | 7.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,298 | 5 | 5.5% |
| Honoraria | $1,500 | 1 | 1.9% |
| Unspecified | $1,249 | 9 | 1.6% |
| Food and Beverage | $1,228 | 25 | 1.6% |
| Education | $163.33 | 7 | 0.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $53,119 | 43 | $0 (2023) |
| ViiV Healthcare Company | $23,550 | 22 | $0 (2023) |
| Theratechnologies Inc. | $2,064 | 5 | $0 (2018) |
| Merck Sharp & Dohme LLC | $54.25 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $5,358 | 3 | ViiV Healthcare Company ($5,319) |
| 2022 | $3,954 | 6 | ViiV Healthcare Company ($3,900) |
| 2021 | $7,050 | 5 | ViiV Healthcare Company ($5,160) |
| 2020 | $13,988 | 3 | Gilead Sciences, Inc. ($10,308) |
| 2019 | $31,132 | 22 | Gilead Sciences, Inc. ($25,641) |
| 2018 | $6,227 | 18 | Gilead Sciences, Inc. ($4,163) |
| 2017 | $11,078 | 18 | Gilead Sciences Inc ($11,078) |
All Payment Transactions
75 individual payment records from CMS Open Payments — Page 2 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/06/2019 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $66.25 | Research |
| Study: A PHASE 3B MULTI-CENTER, OPEN LABEL, SINGLE ARM, 48-WEEK STUDY, EVALUA | ||||||
| 05/14/2019 | ViiV Healthcare Company | — | — | In-kind items and services | $516.60 | Research |
| Study: A PHASE 3B MULTI-CENTER, OPEN LABEL, SINGLE ARM, 48-WEEK STUDY, EVALUA | ||||||
| 05/14/2019 | ViiV Healthcare Company | — | — | In-kind items and services | $270.07 | Research |
| Study: A PHASE 3B MULTI-CENTER, OPEN LABEL, SINGLE ARM, 48-WEEK STUDY, EVALUA | ||||||
| 05/14/2019 | ViiV Healthcare Company | — | — | In-kind items and services | $143.40 | Research |
| Study: A PHASE 3B MULTI-CENTER, OPEN LABEL, SINGLE ARM, 48-WEEK STUDY, EVALUA | ||||||
| 05/14/2019 | ViiV Healthcare Company | — | — | In-kind items and services | $52.03 | Research |
| Study: A PHASE 3B MULTI-CENTER, OPEN LABEL, SINGLE ARM, 48-WEEK STUDY, EVALUA | ||||||
| 05/14/2019 | ViiV Healthcare Company | — | — | In-kind items and services | $38.59 | Research |
| Study: A PHASE 3B MULTI-CENTER, OPEN LABEL, SINGLE ARM, 48-WEEK STUDY, EVALUA | ||||||
| 05/14/2019 | ViiV Healthcare Company | — | — | In-kind items and services | $31.42 | Research |
| Study: A PHASE 3B MULTI-CENTER, OPEN LABEL, SINGLE ARM, 48-WEEK STUDY, EVALUA | ||||||
| 05/14/2019 | ViiV Healthcare Company | — | — | In-kind items and services | $22.45 | Research |
| Study: A PHASE 3B MULTI-CENTER, OPEN LABEL, SINGLE ARM, 48-WEEK STUDY, EVALUA | ||||||
| 04/11/2019 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $3,680.00 | General |
| 04/11/2019 | ViiV Healthcare Company | — | Travel and Lodging | Cash or cash equivalent | $403.92 | General |
| 03/15/2019 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $66.02 | General |
| 03/15/2019 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $48.95 | General |
| 03/15/2019 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $26.18 | General |
| 03/15/2019 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $16.79 | General |
| 10/30/2018 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $39.00 | General |
| 10/30/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.68 | General |
| 10/30/2018 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $28.50 | General |
| 10/30/2018 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $27.00 | General |
| 10/30/2018 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $22.00 | General |
| 10/30/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.47 | General |
| 10/05/2018 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| 09/29/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $37.38 | General |
| 09/29/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.00 | General |
| 09/29/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.00 | General |
| 09/28/2018 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $305.87 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3B MULTI-CENTER, OPEN LABEL, SINGLE ARM, 48-WEEK STUDY, EVALUA | ViiV Healthcare Company | $1,249 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 43 | 72 | $22,223 | $5,436 |
| 2022 | 1 | 14 | 29 | $7,598 | $1,863 |
| 2021 | 2 | 29 | 47 | $12,029 | $3,010 |
| 2020 | 2 | 27 | 50 | $12,770 | $2,801 |
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 32 | $7,904 | $2,183 | 27.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 29 | $7,598 | $1,711 | 22.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $6,721 | $1,542 | 22.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 14 | 29 | $7,598 | $1,863 | 24.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 28 | $7,336 | $1,815 | 24.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 19 | $4,693 | $1,195 | 25.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 22 | $5,434 | $1,403 | 25.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 16 | 28 | $7,336 | $1,398 | 19.1% |
About Dr. Shobha Swaminathan, M.D
Dr. Shobha Swaminathan, M.D is a Infectious Disease healthcare provider based in Newark, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275564411.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shobha Swaminathan, M.D has received a total of $78,788 in payments from pharmaceutical and medical device companies, with $5,358 received in 2023. These payments were reported across 75 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($64,621).
As a Medicare-enrolled provider, Swaminathan has provided services to 113 Medicare beneficiaries, totaling 198 services with total Medicare billing of $13,110. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Newark, NJ
- Active Since 07/05/2006
- Last Updated 02/03/2022
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1275564411
Products in Payments
- CABENUVA (Biological) $7,719
- DOVATO (Drug) $6,660
- TROGARZO (Drug) $1,961
- Veklury (Drug) $1,890
- EGRIFTA (Drug) $103.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Newark
Dr. Jihad Slim, Md, MD
Infectious Disease — Payments: $2.2M
Dr. Maria Szabela, Md, MD
Infectious Disease — Payments: $336,664
Sally Hodder, M.d, M.D
Infectious Disease — Payments: $93,382
Wanda Figueroa, M.d, M.D
Infectious Disease — Payments: $13,660
Alexander Stoler, M.d, M.D
Infectious Disease — Payments: $5,931
Dr. Wesley Emmons, M.d, M.D
Infectious Disease — Payments: $3,509